Trial Spotlight

BRUIN CLL-322; NCT04965493

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma*

See Trial

Trial Spotlight

NCT05614739

An Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Advanced Solid Tumor Malignancies With FGFR3 Alterations*

See Trial

Trial Spotlight

NCT04956640

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors*

See Trial

Trial Spotlight

SUNRAY-01; NCT06119581

A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression*

See Trial

Trial Spotlight

PIKASSO-01; NCT05307705

A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation*

See Trial

Trial Spotlight

EMBER-4; NCT05514054

A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence*

See Trial

BRUIN CLL-322; NCT04965493

NCT05614739

NCT04956640

SUNRAY-01; NCT06119581

PIKASSO-01; NCT05307705

EMBER-4; NCT05514054

Filter our pipeline to find information relevant to you. Search results will appear below.

Breast

Gastrointestinal

Genitourinary

Gynecologic

Hematologic

Lung

Other Solid Tumors

Sarcoma

Thyroid